Inclusion criteria:

          -  Histologically or cytologically confirmed diagnosis of an advanced, unresectable
             and/or metastatic non-haematologic malignancy. Patient must have measurable or
             evaluable lesions (according to Response Evaluation Criteria in Solid Tumours (RECIST)
             v 1.1).

          -  Patient who has failed conventional treatment or for whom no therapy of proven
             efficacy exists or who is not eligible for established treatment options.

          -  Patients willing to undergo mandatory tumour biopsy at the time points specified in
             the protocol.

          -  Eastern Cooperative Oncology Group (ECOG) Score of 0 or 1 (R01-0787).

          -  Adequate organ function defined as all of the following:

               -  Absolute neutrophil count (ANC) ≥1.5 x 10^9/L; haemoglobin ≥9.0 g/dL; platelets
                  ≥100 x 10^9/L without the use of haematopoietic growth factors within 4 weeks of
                  start of study medication.

               -  Total bilirubin ≤1.5 x the upper limit of normal (ULN), except for patients with
                  Gilbert's syndrome: total bilirubin ≤3 x ULN or direct bilirubin ≤1.5 x ULN.

               -  Creatinine ≤1.5 x ULN. If creatinine is >1.5 x ULN, patient is eligible if
                  concurrent creatinine clearance ≥50 ml/min (measured or calculated by the Chronic
                  Kidney Disease Epidemiology Collaboration (CKD-EPI) formula or Japanese version
                  of CKD-EPI formula for Japanese patients).

               -  Aspartate transaminase (AST) and alanine transaminase (ALT) ≤3 x ULN if no
                  demonstrable liver metastases, or otherwise ≤5 x ULN

               -  Alkaline Phosphatase (ALP) <5 x ULN

          -  At least 18 years of age at the time of consent or over the legal age of consent in
             countries where that is greater than 18 years.

          -  Signed and dated written informed consent in accordance with International Conference
             on Harmonisation (ICH) - Good Clinical Practice (GCP) and local legislation prior to
             admission to the trial

          -  Life expectancy ≥3 months at the start of treatment in the opinion of the investigator

          -  Further inclusion criteria apply

        Exclusion criteria:

          -  Osteoporosis ≥ CTCAE Grade 2

          -  Osteoporotic compression fracture within 12 months prior to informed consent which is
             clinically significant in the opinion of the investigator.

          -  Further exclusion criteria apply